ResMed is a current holding in our ASX 100 model portfolio.
The company reports 1Q20 earnings on 25 October and we expect revenue growth to be 15%+ and EBIT to be up 10%+ on the same time last year.
We look for an entry-level into RMD on the current price weakness and will update our readers further, following the earnings result.
ResMed is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.
RMD report earnings on the 24th Oct and the market is looking for 10%+ in EPS growth. We expect buying support to increase ahead of the result and see support building at $19.50.
ResMed is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.
Buying interest is again building near the $14.00 price range.
We recommend adding Resmed to your watch list.
RMDis a global company involved in the development and manufacturing of medical products for the treatment of respiratory disorders. Global mask sales increased 10%+ on the same time last year.
Low returns from new acquisitions, disappointed investors and the soft 2Q19 earnings update resulted in the stock falling by over 10%
It’s difficult to say with certainly where buyers will step back in, but we are confident of the long-term story with Resmed.
The chart below illustrates the lower band where we see deep value for investors willing to take a 1 – 3 year outlook.
RMD has rallied from $13.75 to $14.75 following last weeks reported strong 1Q19 result, which included EBIT +28% on the same time last year.
The company also delivered robust top-line growth, which came in ahead of market expectations. Gross margins held at 58+%.
We anticipate EPS growing from US$3.70 in FY19 to US$4.50 in FY21 and revenue growing from US$2.9 billion to US$3.5 billion over the same period.
Resmed
Resmed should continue to deliver 10% EPS growth per year over the next 2 – 3 years.
However, at 27x F19 earnings and 1.5% yield, the stock looks expensive.
Other names within the Healthcare space such as CSL at 32x and COH at 38x FY19 also, look expensive.
With the above in mind, our base case is that the sector trades sideways and investors should add a covered call option to enhance the returns.
Resmed
Our Algo Engine has triggered buy signals in Sonic Healthcare, Resmed and CSL over the past few trading sessions.
RMD has experienced its first sell-off since rallying from $10 last year to $16 only a few weeks ago.
The ALGO engine is now flagging the new “higher low” at $14 and we suggest buying a 1/2 size allocation here and then waiting to see if we get another ALGO signal to add to the position.
CSL provides good long-term fundamentals. The PE is still expensive, however, 10 – 20% EPS growth is attractive! Accumulate at $180
SHL looks to be good value at $23. We see resistance is $25, so look to sell call options to enhance the return.
Chart: RMD
Chart: CSL
Chart: SHL
Resmed has formed a higher low formation following an increase in buying support at $10.87.
We recommend buying RMD and placing a stop loss below $10.75.
Resmed
CSL, SHL, RMD & RHC remain our preferred healthcare names.
Resmed is looking a little expensive and we’d like to repurchase on the next retracement.
Sonic Healthcare: we expect 5 – 8% EPS growth and consider this a good buy/write addition to portfolios.
Ramsey Healthcare – Accumulate with $74 price target
CSL: 15 – 20% EPS growth remains attractive and adding a covered call option enhances the yield.
CSL
Global mask sales were weaker than expectations, but we see F18 device and mask growth rebounding.
FY18 revenue is forecast to grow by of 5%+ and underlying EPS growth in the high single digits.
RMD is trading at 24x F18 EPS and we see the current sell-off as a buying opportunity.
We need to give this name a wide range to find support and the buying zone is between $8.50 and $9.25. 1, 2 & 3 years out, the stock will be trading at higher prices. Keep an eye out for the next Algo buy signal in RMD!
Level 29 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453
Or start a free thirty day trial for our full service, which includes our ASX Research.